10-[4-(4-methylpiperazino)butyl]phenothiazine | 4708-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 10-[4-(4-methylpiperazino)butyl]phenothiazine
• 英文别名: 10-[4-(4-methyl-piperazino)-butyl]-phenothiazine；10-[4-(4-Methyl-piperazino)-butyl]-phenothiazin；10-[4-(4-Methyl-piperazin-1-yl)-butyl]phenothiazine；10-[4-(4-Methylpiperazin-1-yl)butyl]phenothiazine
• CAS: 4708-16-1
• 化学式: C₂₁H₂₇N₃S
• 分子量: 353.531
• InChiKey: ZKHCDKLHSIZAQE-UHFFFAOYSA-N

物化性质

• 沸点：
  503.4±45.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  10-[4-(4-methylpiperazino)butyl]phenothiazine 、 顺丁烯二酸 以 乙醚 为溶剂， 生成 10-[4-(4-methylpiperazino)butyl]phenothiazine bis-(hydrogen maleate)
  参考文献：
  名称：

  作为 MDR 逆转剂的新型吩噻嗪和相关药物的合成和生化表征

  摘要：

  化疗是治疗癌症最重要的方法之一。然而，化疗期间耐药性的发展是癌症患者治疗失败和生存率下降的主要原因。多药耐药 (MDR) 是 30 多年来广泛研究的耐药形式之一。ATP 结合盒蛋白家族的成员负责以 P-糖蛋白作为最具代表性的转运蛋白的多药耐药性。为了克服多药耐药性，外排泵抑制剂对转运蛋白的药理学调节似乎是首选，但临床前研究并未导致临床应用。因此，对药效基团结构进行系统研究是提高那些仍影响多药耐药性的药物疗效的有前途的策略。在这项研究中，一系列吩噻嗪衍生物合成了三个分子结构域的系统变异。多药耐药逆转活性的生化测定是通过对 LLC-PK1/MDR1 细胞的结晶紫测定实现的。将考虑文献中关于新的结构-活性关系以克服未来耐药性的假设来讨论结果。

  DOI：

  10.1002/ardp.200800115
• 作为产物：
  描述：

  10-[4-[(tetrahydropyran-2-yl)oxy]butyl]-10H-phenothiazine 在 氯化亚砜 、 4-甲基苯磺酸吡啶 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 苯 为溶剂， 反应 4.0h， 生成 10-[4-(4-methylpiperazino)butyl]phenothiazine
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of New Chemosensitizers in Multi-Drug-Resistant Plasmodium falciparum

  摘要：

  A series of new chemosensitizers (modulators) against chloroquine-resistant Plasmodium falciparum were designed and synthesized in an attempt to fabricate modulators with enhancing drug-resistant reversing efficacy and minimal side effects. Four aromatic amine ring systems-phenothiazine, iminodibenzyl, iminostilbene, and diphenylamine-were examined. Various tertiary amino groups including either noncyclic or cyclic aliphatic amines were introduced to explore the steric tolerance at the end of the side chain. The new compounds showed better drug-resistant reversing activity in chloroquine-resistant than in mefloquine-resistant cell lines and were generally more effective against chloroquine-resistant P. falciparum isolates from Southeast Asian (W2 and TM91C235) than those from South America (PC49 and RCS). Structure-activity relationship studies revealed that elongation of the alkyl side chain of the molecule retained the chemosensitizing activity, and analogues with four-carbon side chains showed superior activity. Furthermore, new modulators with phenothiazine ring exhibited the best chemosensitizing activity among the four different ring systems examined. Terminal amino function has limited steric tolerance as evidenced by the dramatic lose of the modulating activity, when the size of substituent at the amino group increases. The best new modulator synthesized in this study possesses all three optimized structural features, which consist of a phenothiazine ring and a pyrrolidinyl group joined by a four-carbon alkyl bridge. The fractional inhibitory concentration TIC) index of the best compound is 0.21, which is superior to that of verapamil (0.51), one of the best-known multi-drug-resistant reversing agents. Some of the analogues displayed moderate intrinsic in vitro antimalarial activity against a W-2 clone of P. falciparum.

  DOI：

  10.1021/jm010549o

文献信息

• Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
  申请人：——

  公开号：US20030032801A1

  公开（公告）日：2003-02-13

  A compound having the structural formula 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein X is a substituted or unsubstituted alkyl or a heteroatom; n is 4, 5 or 6; Y is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or 2 wherein R 1 and R 2 are each independently, H, a heteroatom, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein each ring structure are independently substituted or unsubstituted is disclosed. Also disclosed are chemosensitizing agents and methods of modulating, attenuating, reversing, or affecting a cell's or organism's resistance to a given drug such as an antimalarial.

  一种具有结构式1的化合物，或其药物可接受的盐或前药，其中X是取代或未取代的烷基或杂原子; n为4、5或6; Y是取代或未取代的烷基、环烷基、杂环烷基、芳基、杂芳基或2，其中R1和R2各自独立地为H、杂原子、取代或未取代的烷基、环烷基、杂环烷基、芳基或杂芳基;并且每个环结构都是独立取代或未取代的。还公开了化学增敏剂和调节、减弱、逆转或影响细胞或生物对给定药物（如抗疟药）的耐药性的方法。
• Untersuchungen �ber Phenthiazinderivate I: �ber die Synthese von 10-Piperazinoalkyl-phenthiazinen
  作者：O. Hromatka、F. Sauter、I. Grass

  DOI：10.1007/bf01075430

  日期：——
• HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：NEUROSEARCH A/S

  公开号：EP1027336B1

  公开（公告）日：2004-10-06
• US6800618B2
  申请人：——

  公开号：US6800618B2

  公开（公告）日：2004-10-05
• [EN] CHEMOSENSITIZING AGENTS AGAINST CHLOROQUINE RESISTANT PLASMODIUM FALCIPARUM AND METHODS OF MAKING AND USING THEREOF<br/>[FR] AGENTS DE CHIMIOSENSIBILISATION CONTRE PLASMODIUM FALCIPARUM RESISTANT A LA CHLOROQUINE ET LEURS PROCEDES D'UTILISATION
  申请人：US ARMY MEDICAL RES AND MATERI

  公开号：WO2002089810A1

  公开（公告）日：2002-11-14

  A compound having the structural formula or a pharmaceutically acceptable salt or prodrug thereof, wherein X is a substituted or unsubstituted alkyl or a heteroatom; n is 4,5 or 6; Y is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or wherein R1 and R2 are each independently, H, a heteroatom, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein each ring structure are independently substituted or unsubstituted is disclosed. Also disclosed are chemosensitizing agents and methods of modulating, attenuating, reversing, or affecting a cell's or organism's resistance to a given drug such as an antimalarial.